Increased expression of lymphocyte activation gene-3 by regulatory t cells in multiple sclerosis patients with fingolimod treatment Multiple sikleroz hastalarında fingolimod tedavisi sonucu düzenleyici t hücrelerinde lenfosit aktivasyon gen-3 ekspresyonunda artı�

Sedaghat, N. and Motedayyen, H. and Alsahebfosoul, F. and Etemadifar, M. and Ostadi, V. and Kianpour, F. and Akbari, M. and Vestri, E. and Zarkesh Esfahani, S.H. (2019) Increased expression of lymphocyte activation gene-3 by regulatory t cells in multiple sclerosis patients with fingolimod treatment Multiple sikleroz hastalarında fingolimod tedavisi sonucu düzenleyici t hücrelerinde lenfosit aktivasyon gen-3 ekspresyonunda artı�. Turkish Journal of Immunology, 7 (1). pp. 31-39.

Full text not available from this repository.
Official URL: https://www.scopus.com/inward/record.uri?eid=2-s2....
DOI: UNSPECIFIED

Abstract

Introduction: Multiple sclerosis (MS) is associated with the failure of peripheral tolerance to self-antigens. Regulatory T cells (Tregs) play a pivotal role in regulating the immune system and inhibiting development of autoimmune diseases. Until now, the effects of fingolimod, an immunomodulator, on different lymphocyte subsets are not fully understood. In this study, we evaluated how fingolimod affects lymphocyte subsets of patients with MS. Material and Methods: Peripheral blood mononuclear cells (PBMCs) were isolated from 20 MS and 12 healthy subjects. The number of white blood cells (WBCs) was assessed using an automated cell counter system. Circulating CD4+ cells, CD4+ FoxP3+ cells, and CD25+ FoxP3+ LAG-3+ Tregs were analyzed by flow cytometry. LAG-3 expression on CD4+ FoxP3+ cells was also determined using flow cytometry. Results: Our data revealed that fingolimod had a suppressive effect on WBC number in MS patients (P=0.0001). Fingolimod statistically significantly reduced rate of CD4+ cells (P=0.0005), while increased the rate of circulating CD4+ Foxp3+ cells (P=0.014) and LAG-3 expressing Tregs (P=0.004) in MS patients. Moreover, fingolimod enhanced LAG-3 expression on CD25+ FoxP3+ cells of patients with MS (P=0.04). Conclusion: Based on these findings, fingolimod can be considered as one of effective therapeutic approaches for increasing the number of Tregs and modulating abnormal immune responses in patients with MS. © 2019 Turkish Journal of Immunology. All rights reserved.

Item Type: Article
Additional Information: cited By 0
Uncontrolled Keywords: CD4 antigen; fingolimod; interleukin 2 receptor alpha; transcription factor FOXP3, adult; Article; CD4+ T lymphocyte; clinical article; controlled study; depression; diplopia; disease duration; Expanded Disability Status Scale; flow cytometry; gene expression; human; human cell; immune response; immune system; leukocyte count; lymphocyte activation; lymphocyte count; multiple sclerosis; non insulin dependent diabetes mellitus; peripheral blood mononuclear cell; protein expression; regulatory T lymphocyte; seizure
Subjects: Biochemistry, Genetics and Molecular Biology
Divisions: Faculty of Medicine > Basic Sciences > Applied Cell Sciences
Depositing User: ART . editor
Date Deposited: 24 Dec 2019 12:02
Last Modified: 24 Dec 2019 12:02
URI: http://eprints.kaums.ac.ir/id/eprint/4819

Actions (login required)

View Item View Item